A Study to Develop a Biobank of Samples from Patients Undergoing Therapy with PCSK9 Inhibitors

Overview

About this study

Develop a biobank of samples from patients undergoing therapy with PCSK9 inhibitors (FDA- approved in 2015, therapeutics for hypercholesterolemia) with the goal of developing laboratory tests which may help identify best candidates for these therapies and aid in monitoring therapy efficacy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  1. Pre-identified dyslipidemic patients selected to receive PCSK9 inhibitor treatment at Mayo Clinic. The drug will be prescribed by a cardiologist as part of the patient’s routine care.

Exclusion Criteria: 

  1. Pediatric patients younger than 18 years of age.
  2. Pregnant women of any age.
  3. Subjects who have not provided MN research authorization.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Leslie Donato, Ph.D.

Open for enrollment

Contact information:

Mohamed Ibrahim

(507)284-4115

Ibrahim.Mohamed@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20360189

Mayo Clinic Footer